{"id":29053,"date":"2024-08-23T10:45:00","date_gmt":"2024-08-23T10:45:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4490150_CN90150_0"},"modified":"2024-08-23T10:45:00","modified_gmt":"2024-08-23T10:45:00","slug":"corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=29053","title":{"rendered":"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)"},"content":{"rendered":"<p><b>The World&#8217;s First-in-Class <\/b><b>Intrauterine Drug-Eluting <\/b><b>System <\/b><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SHANGHAI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 23, 2024<\/span><\/span> \/PRNewswire\/ &#8212; <b>Corina Intrauterine Drug-Eluting <\/b><b>System<\/b><b>&nbsp;(&#8220;Corina&#8221;),<\/b> developed by Yipurun (<span class=\"xn-location\">Shanghai<\/span>) Biotechnology Co., Ltd. (&#8220;YPR&#8221;), has received approval in <span class=\"xn-location\">China<\/span> (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA)&nbsp;who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a randomized controlled clinical trial that demonstrated Corina&#8217;s superior&nbsp;efficacy compared to the standard-of-care. Corina is a first-in-class treatment focused on promoting female reproductive health through the prevention of intrauterine re-adhesion risk post TCRA, and the improvement of endometrial growth.<\/p>\n<p>Intrauterine adhesions (IUA) are the formation of scar tissues in the endometrial cavity as a result of damages to the endometrial basal layer of the uterus, which leads to the partial or complete occlusion of the cervical canal and uterine cavity. Clinically, IUA can cause a range of symptoms such as reduced menstrual flow, amenorrhea, infertility and recurrent miscarriage&nbsp;\u2013 thereby&nbsp;posing a serious threat to the reproductive health of women of childbearing age. Currently, the incidence rate of IUA in <span class=\"xn-location\">China<\/span> remains high, and continues to grow due to an increased number of intrauterine interventions. Research in this field show the incidence rate of IUA in <span class=\"xn-location\">China<\/span> to be as high as 25% in women who have had prior abortion&nbsp;or curettage procedures <sup>[1]<\/sup>&nbsp;\u2014 this has become a key driver of reduced menstrual flow and secondary infertility&nbsp;in women of childbearing age.&nbsp;As a standard surgical procedure to treat&nbsp;IUA, TCRA separates the adherent tissues and restores the anatomical shape of the uterine cavity. Surveys show&nbsp;1.6 to 1.8 million patients in <span class=\"xn-location\">China<\/span> undergo&nbsp;TCRA every year, but the recurrence rate of IUA after surgery is still as high as 62.5%&nbsp;<sup>[2]<\/sup>; and the pregnancy success rate of patients after TCRA surgery is only 22.5%~33.3%&nbsp;<sup>[3-4]<\/sup>.&nbsp;Over the years, a variety of adjuvant therapies, such as uterine cavity isolation barriers and hormonal treatments, have emerged with limited efficacy.<\/p>\n<p>Corina is an innovative drug-device-combination therapy made from non-degradable, medical grade material, carrying the active ingredient estradiol. Designed to conform to the shape of the female uterus, Corina acts as a physical barrier upon insertion,&nbsp;and enables targeted delivery of estradiol to the endometrium. With YPR&#8217;s proprietary controlled-release technology, Corina can continuously release&nbsp;the active substance up to 60 days post procedure&nbsp;to promote endometrium growth.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2111\" readability=\"9\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2488376\/Corina_acts_a_physical_barrier_insertion_enables_targeted_delivery_estradiol.html\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2488376\/Corina_acts_a_physical_barrier_insertion_enables_targeted_delivery_estradiol.jpg?p=medium600\" title=\"Corina acts as a physical barrier upon insertion, and enables targeted delivery of estradiol to the endometrium\" alt=\"Corina acts as a physical barrier upon insertion, and enables targeted delivery of estradiol to the endometrium\"><\/a><br \/><span>Corina acts as a physical barrier upon insertion, and enables targeted delivery of estradiol to the endometrium<\/span><\/p>\n<\/p><\/div>\n<p>The registration study results of Corina&nbsp;have demonstrated statistically significant and clinically meaningful reduction in intrauterine adhesion at 60 days post procedure, compared to standard-of-care therapy. Corina has also shown meaningful improvement in endometrial thickness from baseline at 60 days post procedure, compared to standard-of-care therapy.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder4559\" readability=\"7\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2488377\/Evaluating_effectiveness_data_clinical_trials.html\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2488377\/Evaluating_effectiveness_data_clinical_trials.jpg?p=medium600\" title=\"Evaluating effectiveness data from clinical trials\" alt=\"Evaluating effectiveness data from clinical trials\"><\/a><br \/><span>Evaluating effectiveness data from clinical trials<\/span><\/p>\n<\/p><\/div>\n<p><b>A<\/b><b>bout Puyi Biotech<\/b><\/p>\n<p>Located in the Zhangjiang Hi-Tech Park in Shanghai,&nbsp;Yipurun (<span class=\"xn-location\">Shanghai<\/span>) Biotechnology Co., Ltd. (&#8216;YPR&#8217;) is a wholly-owned subsidiary of Puyi (<span class=\"xn-location\">Shanghai<\/span>) Biotechnology Co., Ltd. (&#8220;Puyi Biotech&#8221;&nbsp;or &#8220;Group&#8221;). Leveraging its knowhow in biomedical material science&nbsp;and its proprietary drug-eluting technology, Puyi Biotech and YPR have developed an innovative R&amp;D pipeline of high-end implantable therapeutics. Since its founding in 2012, Puyi Biotech has focused on providing innovative solutions to address unmet clinical needs&nbsp;across&nbsp;women&#8217;s health, ENT (ear, nose and throat), and medical aesthetics&nbsp;categories. The Group has a number of renowned institutions as investors including Goldman Sachs Alternatives, Legend Capital and Northern Light VC.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody readability=\"14\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">References<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[1] &nbsp;2015 Chinese expert consensus on the clinical diagnosis and treatment of intrauterine adhesions<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"12\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"11\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[2] Yu&nbsp;D&nbsp;,&nbsp;Wong&nbsp;YM&nbsp;,&nbsp;Cheong&nbsp;Y&nbsp;,et al.&nbsp;Asherman syndrome: one century later[J].&nbsp;Fertil Steril,&nbsp;2008,89(4):759\u2013779.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"12\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"11\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[3] Yu&nbsp;D&nbsp;,&nbsp;Li&nbsp;TC&nbsp;,&nbsp;Xia&nbsp;E&nbsp;,et al.&nbsp;Factors affecting reproductive outcome of hysteroscopic adhesiolysis for Asherman&#8217;s syndrome[J].&nbsp;Fertil Steril,&nbsp;2008,89(3):715\u2013722.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"13.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"12\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[4] Roy&nbsp;KK&nbsp;,&nbsp;Baruah&nbsp;J&nbsp;,&nbsp;Sharma&nbsp;JB&nbsp;,et al.&nbsp;Reproductive outcome following hysteroscopic adhesiolysis in patients with infertility due to Asherman&#8217;s syndrome[J].&nbsp;Arch Gynecol Obstet,&nbsp;2010,281(2):355\u2013361.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>Contact Us<br \/>Address: Room 2206, No. 396, Lishizhen Road, Pudong New Area, <span class=\"xn-location\">Shanghai, China<\/span><br \/>Company Contact Tel: +86-21-50805520, Merchants Phone: +86-21-58556388<br \/>Website: en.puyibio.com<br \/>Email: <a href=\"mailto:service@puyibio.com\" target=\"_blank\" rel=\"nofollow noopener\">service@puyibio.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The World&#8217;s First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 \/PRNewswire\/ &#8212; Corina Intrauterine Drug-Eluting System&nbsp;(&#8220;Corina&#8221;), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. (&#8220;YPR&#8221;), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA)&nbsp;who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":29054,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-29053","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA) - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=29053\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA) - My Blog\" \/>\n<meta property=\"og:description\" content=\"The World&#8217;s First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 \/PRNewswire\/ &#8212; Corina Intrauterine Drug-Eluting System&nbsp;(&#8220;Corina&#8221;), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. (&#8220;YPR&#8221;), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA)&nbsp;who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=29053\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-23T10:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2488376\/Corina_acts_a_physical_barrier_insertion_enables_targeted_delivery_estradiol.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)\",\"datePublished\":\"2024-08-23T10:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053\"},\"wordCount\":737,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053\",\"name\":\"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA) - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg\",\"datePublished\":\"2024-08-23T10:45:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg\",\"width\":598,\"height\":220},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=29053#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA) - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=29053","og_locale":"en_US","og_type":"article","og_title":"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA) - My Blog","og_description":"The World&#8217;s First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 \/PRNewswire\/ &#8212; Corina Intrauterine Drug-Eluting System&nbsp;(&#8220;Corina&#8221;), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. (&#8220;YPR&#8221;), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA)&nbsp;who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=29053","og_site_name":"My Blog","article_published_time":"2024-08-23T10:45:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2488376\/Corina_acts_a_physical_barrier_insertion_enables_targeted_delivery_estradiol.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=29053#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=29053"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)","datePublished":"2024-08-23T10:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=29053"},"wordCount":737,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=29053#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/08\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=29053","url":"https:\/\/transmediavictoria.net.au\/?p=29053","name":"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA) - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=29053#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=29053#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/08\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg","datePublished":"2024-08-23T10:45:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=29053#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=29053"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=29053#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/08\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/08\/corina-intrauterine-drug-eluting-system-approved-in-china-as-a-novel-treatment-for-patients-with-moderate-to-severe-intrauterine-adhesions-iua.jpg","width":598,"height":220},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=29053#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/29053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29053"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/29053\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/29054"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}